Suven Life Sciences Limited (SUVEN) Price & Analysis

Compare

3 Followers

SUVEN Stock Chart & Stats

₹165.00

₹14.56(11.52%)

At close: Jan 08 4:00 PM EST

₹165.00

₹14.56(11.52%)

Day’s Range― - ―

52-Week Range₹112.55 - ₹303.00

Previous CloseN/A

Volume2.87M

Average Volume (3M)14.83K

Market Cap

₹31.88B

Enterprise Value₹31.90B

Total Cash (Recent Filing)₹2.59B

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)―

Beta1.64

Next Earnings

Apr 30, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-4.48

Shares Outstanding231,951,810

10 Day Avg. Volume16,308

30 Day Avg. Volume14,834

Financial Highlights & Ratios

PEG Ratio-0.31

Price to Book (P/B)24.25

Price to Sales (P/S)400.69

P/FCF Ratio-14.36

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low LeverageNear-zero debt materially reduces solvency and interest burden, giving management durable flexibility to fund operations, restructure contracts, or raise capital without immediate creditor pressure. This low-leverage profile limits short-term default risk and preserves options during a multi-quarter turnaround.

Specialized R&D CapabilitiesDeep medicinal-chemistry and discovery capabilities represent high-barrier, knowledge-intensive services that create client stickiness and differentiation. Over several months this expertise supports repeat project wins, higher switching costs for customers, and potential to expand into adjacent discovery services.

Fee-based Contract ModelA fee- and milestone-based CRO model yields contractual revenue streams tied to deliverables, reducing reliance on single-product commercialization. Combined with the structural trend to outsource discovery, this model can provide repeatable project flows and predictable mid-term revenue if sales and delivery execution improve.

Bears Say

Revenue & Margin DeteriorationA double hit of falling revenue and negative gross profit signals fundamental pricing, cost, or mix problems. Sustained margin erosion undermines ability to generate operating profits even if top-line stabilizes; without structural contract wins or cost realignment, return to profitability is unlikely within several quarters.

Persistent Cash BurnConsistently negative operating and free cash flow shows the business is not self-funding and is burning liquidity. This persistent cash drain forces reliance on external financing or asset disposals, constraining investments in client projects and R&D, and raising solvency and dilution risk over the medium term.

Equity ErosionSharp equity decline and deeply negative ROE indicate capital buffer erosion from sustained losses. Weaker equity reduces the firm's capacity to absorb further setbacks, makes future fundraising more dilutive or costly, and impairs credibility with clients and lenders over a multi-quarter horizon.

Suven Life Sciences Limited News

Suven Life Sciences Opens Special Window for Re-Lodgment of Physical Share Transfers

Suven Life Sciences Limited ( ($IN:SUVEN) ) just unveiled an update. Suven Life Sciences has notified stock exchanges...

25d ago

SUVEN

Suven Life Sciences Attributes Share Price Surge to Market Speculation

Suven Life Sciences Limited ( ($IN:SUVEN) ) has shared an announcement. Suven Life Sciences Limited has responded to...

1M ago

SUVEN

SUVEN FAQ

What was Suven Life Sciences Limited’s price range in the past 12 months?

Suven Life Sciences Limited lowest stock price was ₹112.55 and its highest was ₹303.00 in the past 12 months.

What is Suven Life Sciences Limited’s market cap?

Suven Life Sciences Limited’s market cap is ₹31.88B.

When is Suven Life Sciences Limited’s upcoming earnings report date?

Suven Life Sciences Limited’s upcoming earnings report date is Apr 30, 2026 which is in 45 days.

How were Suven Life Sciences Limited’s earnings last quarter?

Suven Life Sciences Limited released its earnings results on Jan 29, 2026. The company reported -₹4.481 earnings per share for the quarter, missing the consensus estimate of N/A by -₹4.481.

Is Suven Life Sciences Limited overvalued?

According to Wall Street analysts Suven Life Sciences Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Suven Life Sciences Limited pay dividends?

Suven Life Sciences Limited pays a Annually dividend of ₹1.382 which represents an annual dividend yield of N/A. See more information on Suven Life Sciences Limited dividends here

What is Suven Life Sciences Limited’s EPS estimate?

Suven Life Sciences Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Suven Life Sciences Limited have?

Suven Life Sciences Limited has 231,951,810 shares outstanding.

What happened to Suven Life Sciences Limited’s price movement after its last earnings report?

Suven Life Sciences Limited reported an EPS of -₹4.481 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.758%.

Which hedge fund is a major shareholder of Suven Life Sciences Limited?

Currently, no hedge funds are holding shares in IN:SUVEN

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Suven Life Sciences Limited

Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities (NCEs) in central nervous system therapies. Its product candidates include SUVN-502 for the treatment of Alzheimer's disease and neuropsychiatric symptoms; SUVN-G3031, a potent and selective histamine H3 receptor inverse agonist for the treatment of sleep and cognitive disorders; and SUVN-911, a novel, potent, and selective a4ß2 nicotinic acetylcholine receptor antagonist for the treatment of depressive disorders. The company is also developing SUVN-D4010, a potent, selective, and orally bio-available and brain penetrant 5-HT4 receptor partial agonist for the treatment of cognitive disorders; SUVN-I6107 for the treatment of cognitive disorders and schizophrenia; SUVN-M8036 for the treatment of psychiatric disorders; and SUVN-D1044 for the treatment of gastrointestinal disorders. The company was formerly known as Suven Pharmaceuticals Pvt. Ltd. and changed its name to Suven Life Sciences Limited in 2003. The company was incorporated in 1989 and is headquartered in Hyderabad, India. Suven Life Sciences Limited is a subsidiary of Jasti Property and Equity Holdings Private Limited.